Prothena Corp Public (PRTA) Cash from Restructuring (2018 - 2026)
Prothena Corp Public's (PRTA) quarterly Cash from Restructuring came in at $480000.0 in Q1 2026, up 111.13% quarter-over-quarter from -$4.3 million in Q4 2025.
Prothena Corp Public (PRTA) Cash from Restructuring (2018 - 2026) Analysis & Trends
Prothena Corp Public's Cash from Restructuring history runs 4 years deep, the most recent figure standing at $480000.0 for Q1 2026.
- On a quarterly basis, Cash from Restructuring changed N/A year-over-year to $480000.0 in Q1 2026; TTM through Mar 2026 was $13.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $13.3 million, changed N/A from the prior year.
- Cash from Restructuring improved to $480000.0 in Q1 2026 per PRTA's latest filing, from -$4.3 million in the prior quarter.
- Across five years, Cash from Restructuring topped out at $30.3 million in Q2 2025 and bottomed at -$12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | -4.31 Mn |
| Sep 30, 2025 | -12.72 Mn |
| Jun 30, 2025 | 30.33 Mn |
| Mar 31, 2019 | -461,000.00 |
| Dec 31, 2018 | -3.88 Mn |
| Sep 30, 2018 | -11.54 Mn |
| Jun 30, 2018 | 15.88 Mn |